Literature DB >> 14603220

P-selectin and leukocyte microparticles are associated with venous thrombogenesis.

Daniel D Myers1, Angela E Hawley, Diana M Farris, Shirley K Wrobleski, Porama Thanaporn, Robert G Schaub, Denisa D Wagner, Anjali Kumar, Thomas W Wakefield.   

Abstract

OBJECTIVES: P-selectin inhibition has been found to limit venous thrombosis. We hypothesize that elevated levels of P-selectin will amplify thrombosis, mediated by procoagulant microparticles (MPs).
METHODS: Male mice (Mus musculus, n659), 20 to 25 grams, underwent IVC ligation to induce thrombosis. Groups consisted of wild type (WT) C57BL/6 controls, mice with high circulating levels of soluble P-selectin (CT), P-selectin gene-interrupted knockout mice (PKO), and E- and P-selectin gene-interrupted mice (EPKO). Additional groups were used to evaluate the ability of a P-sel antagonist (rPSGL-Ig) and an antibody directed against PSGL-1 to downregulate the effects of P-sel in CT mice and WT mice administered soluble P-sel at time of thrombosis. Animals were sacrificed on days 2 and 6 after IVC ligation. Thrombus mass (TM), vein wall morphometrics, and serum leukocyte/platelet microparticles (MPs) were evaluated by means of double-stained fluorescence-activated cell scanning analysis, and soluble P- and E-sel protein determination by ELISA.
RESULTS: At days 2 and 6 in phase I of the experiment, significant differences (P <.01) in TM were noted between groups, with CT animals having the largest thrombi (50% and 57% increase in TM compared to WT at days 2 and 6) while EPKO mice had the smallest thrombi. Statistically, greater levels of neutrophils and total inflammatory cells were noted in the vein walls of CT animals at day 2 compared with WT and PKO animals. A significant difference was noted between CT and EPKO for neutrophils, monocytes, and total inflammatory cells, also at day 2. At day 6, the only statistically significant difference was found for monocytes, with a higher number in the CT animals than in WT animals. The evaluation of MPs revealed that the CT mice had a mixed leukocyte (MAC-1) and platelet (CD41) MP population that was also present in WT and PKO mice on day 2 and day 6. EPKO mice revealed a primarily platelet-derived MP population. Of interest, the CT mice with the highest TM showed a high amount of mean channel fluorescence for MAC-1 (phycoerythrin) antibody, indicative of leukocyte MPs. CT mice revealed statistically higher levels of soluble P-selectin at days 2 and 6. In phase 2, an antibody directed against PSGL-1 was more effective than rPSGL-Ig in decreasing TM and limiting leukocyte-derived MP fluorescence.
CONCLUSIONS: This study demonstrates that high circulating levels of P-selectin are associated with increased thrombosis, whereas a lack of P-selectin and E-selectin is associated with a lessening of thrombosis. Additionally, leukocyte MPs are associated with venous thrombus formation. These data suggest the importance of selectins to venous thrombogenesis and show that P-selectin and leukocyte-derived MPs should be good targets to limit venous thrombus formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14603220     DOI: 10.1016/s0741-5214(03)01033-4

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  60 in total

1.  Thrombophilia in ischemic stroke subtypes: implications for treatment.

Authors:  Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

2.  The association of P-selectin glycoprotein ligand-1 VNTR polymorphisms with coronary stent restenosis.

Authors:  Beste Ozben; Reyhan Diz-Kucukkaya; Ahmet K Bilge; Veysel S Hancer; Aytac Oncul
Journal:  J Thromb Thrombolysis       Date:  2007-06       Impact factor: 2.300

Review 3.  Re-Examining Neutrophil Participation in GN.

Authors:  Dawn J Caster; David W Powell; Irina Miralda; Richard A Ward; Kenneth R McLeish
Journal:  J Am Soc Nephrol       Date:  2017-06-15       Impact factor: 10.121

4.  Circulating soluble P-selectin must dimerize to promote inflammation and coagulation in mice.

Authors:  Sumith R Panicker; Padmaja Mehta-D'souza; Nan Zhang; Arkadiusz G Klopocki; Bojing Shao; Rodger P McEver
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

Review 5.  Deep vein thrombosis: pathogenesis, diagnosis, and medical management.

Authors:  Jonathan Stone; Patrick Hangge; Hassan Albadawi; Alex Wallace; Fadi Shamoun; M Grace Knuttien; Sailendra Naidu; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 6.  Animal models of venous thrombosis.

Authors:  Hassan Albadawi; Avery A Witting; Yash Pershad; Alex Wallace; Andrew R Fleck; Peter Hoang; Ali Khademhosseini; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 7.  Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.

Authors:  Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

8.  P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.

Authors:  Eduardo Ramacciotti; Daniel D Myers; Shirley K Wrobleski; K Barry Deatrick; Frank J Londy; John E Rectenwald; Peter K Henke; Robert G Schaub; Thomas W Wakefield
Journal:  Thromb Res       Date:  2009-12-04       Impact factor: 3.944

9.  Anti-inflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice.

Authors:  S Crikis; X M Zhang; S Dezfouli; K M Dwyer; L M Murray-Segal; E Salvaris; C Selan; S C Robson; H H Nandurkar; P J Cowan; A J F d'Apice
Journal:  Am J Transplant       Date:  2010-01-06       Impact factor: 8.086

10.  Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo.

Authors:  Grace M Thomas; Laurence Panicot-Dubois; Romaric Lacroix; Françoise Dignat-George; Dominique Lombardo; Christophe Dubois
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.